Jennifer Buell - 02 Jan 2026 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role: Chief Executive Officer
Signature: By: /s/ Austin Charette, Attorney-in-Fact
Issuer symbol: INKT
Transactions as of: 02 Jan 2026
Net transactions value: +$349,991
Form type: 4
Filing time: 06 Jan 2026, 17:27:03 UTC
Previous filing: 03 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Buell Jennifer	Chief Executive Officer	149 FIFTH AVENUE, SUITE 500, NEW YORK	By: /s/ Austin Charette, Attorney-in-Fact	06 Jan 2026	0001711184

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INKT	Common Stock	Award	$349,991	+31,474	+86%	$11.12	67,966	02 Jan 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INKT	Stock Option (Right to Buy)	Award	$0	+50,000		$0.000000	50,000	02 Jan 2026	Common Stock	50,000	$11.12	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the executive's 2025 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on February 2, 2026.
F2	$11.12 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 2, 2026, the stock issuance date.
F3	The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the date of grant, with the remainder vesting in eight equal quarterly installments thereafter.